Non-injectable Insulin Market Trends Are Creating New Opportunities For Industry Leaders
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Non-injectable Insulin Market Expected To Reach $3.4 Billion By 2030 At 9.8% CAGR
The market for non-injectable insulin has experienced robust expansion in recent years. Valued at $2.14 billion in 2025, it is anticipated to climb to $2.35 billion by 2026, representing a compound annual growth rate (CAGR) of 9.9%. Several key drivers have fueled this historical progress, such as the growing incidence of diabetes, an increased patient demand for needle-free treatment options, breakthroughs in insulin formulation technologies, public health efforts that promote better diabetes care, and a deeper understanding of the illness’s complications.
The non-injectable insulin market is projected to experience robust expansion over the coming years, reaching $3.41 billion by 2030 with a compound annual growth rate (CAGR) of 9.8%. This forecasted growth is driven by advances in oral and inhalable insulin technologies, the incorporation of digital health tools, an increasing elderly population, improved healthcare systems in developing nations, and tailored diabetes therapies. Key developments shaping the period ahead encompass oral insulin delivery platforms, pulmonary inhalers for insulin administration, diabetes care focused on patient needs, non-invasive methods for monitoring and dosing, and formulation breakthroughs designed to enhance bioavailability.
Download A Free Sample Report For Comprehensive Market Insights:
Non-injectable Insulin Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing prevalence of obesity and diabetes is set to drive expansion in the non-injectable insulin market in the coming years. Obesity involves an abnormal buildup of body fat, often stemming from a mismatch between caloric intake and energy use, while diabetes mellitus, commonly shortened to diabetes, refers to a set of metabolic conditions marked by sustained high blood glucose levels. Non-injectable insulin serves as a treatment option for both diabetes and obesity, offering the potential to improve disease management by overcoming obstacles to insulin use, assisting with weight control, and delivering more convenient therapeutic choices. For example, in June 2023, the Institute for Health Metrics and Evaluation, a public health research institute based in the United States, reported that over 500 million people around the world were living with diabetes. That figure is projected to more than double by 2050, reaching 1.3 billion individuals. Consequently, the rising rates of obesity and diabetes are fueling growth in the market for non-injectable insulin.
Non-injectable Insulin Market Segmentation Trends And Revenue Drivers
The non-injectable insulin market covered in this report is segmented –
1) By Insulin Type: Oral Insulin, Inhaled Insulin, Nasal Insulin, Buccal Or Sublingual Insulin, Transdermal Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Oral Insulin: Oral Insulin Tablets, Oral Insulin Capsules, Enteric-Coated Oral Insulin, Nanoparticle-Based Oral Insulin
2) By Inhaled Insulin: Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems
3) By Nasal Insulin: Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin
4) By Buccal Or Sublingual Insulin: Buccal Spray Insulin, Sublingual Insulin Films, Oral Mucosal Insulin Drops
5) By Transdermal Insulin: Insulin Patches, Microneedle-Free Transdermal Systems, Iontophoresis-Based Insulin Delivery
Non-injectable Insulin Market Trends: What Is Shaping Future Industry Growth?
Leading players in the non-injectable insulin sector are concentrating on novel breakthroughs in drug delivery systems—including needle-free oral insulin sprays—aimed at enhancing the quality of life for individuals managing diabetes through multiple daily injections. As a painless and injection-free method for controlling blood sugar, a needle-free insulin spray provides a practical solution since doses can be administered directly into the oral cavity. For example, in November 2023, NiedlFree Technologies, a tech firm based in India, launched Ozulin, an oral insulin spray. This product is designed to offer a more accessible option for diabetic patients, especially those who struggle with conventional injectable insulin methods. Should it receive approval, Ozulin could transform diabetes management by delivering a more convenient and discomfort-free substitute for injectable insulin.
Non-injectable Insulin Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.
Access The Complete Non-injectable Insulin Market Report:
Non-injectable Insulin Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
